Scarica l'app Stockscreener
20.05
0.59%
-0.0502
Precedente Chiudi:
$20.10
Aprire:
$20.11
Volume 24 ore:
389.99K
Relative Volume:
0.26
Capitalizzazione di mercato:
$1.78B
Reddito:
$172.60M
Utile/perdita netta:
$-285.42M
Rapporto P/E:
-6.0825
EPS:
-3.2963
Flusso di cassa netto:
$-323.17M
1 W Prestazione:
-3.15%
1M Prestazione:
-17.74%
6M Prestazione:
+36.02%
1 anno Prestazione:
+87.79%
Intervallo 1D:
$19.66
$20.32
Intervallo di 1 settimana:
$19.00
$21.55
Portata 52W:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.05 | 1.78B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
428.19 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.78 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.61 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.16 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
MSN Money - MSN
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance
Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory By Investing.com - Investing.com Canada
Jefferies cuts Syndax Pharmaceuticals price target on transplant impact By Investing.com - Investing.com Canada
SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%Time to Sell? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 - MarketBeat
Syndax Pharmaceuticals stock price target raised to $29 by BofA - Investing.com Australia
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus
SNDX SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Earnings Call Summary | Syndax Pharmaceuticals(SNDX.US) Q1 2026 Earnings Conference - Moomoo
Syndax Pharmaceuticals (SNDX) Reports Strong Q1 2026 Earnings an - GuruFocus
Syndax Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results - MarketBeat
SNDX Sees Strong Demand Despite Q1 Revenue Miss - GuruFocus
How Should Investors Value Syndax Pharmaceuticals (SNDX) After Q - GuruFocus
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss - marketscreener.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Syndax (NASDAQ: SNDX) details 2026 virtual meeting, director votes and 7.2M-share plan - Stock Titan
Q1 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
SNDX: Revenue up 224% to $64.9M; net loss halved; strong growth in Revuforj and Niktimvo sales - TradingView
Syndax: Q1 Earnings Snapshot - KVUE
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q1 Revenue $64.9M, vs. FactSet Est of $69.8M - marketscreener.com
Syndax Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Syndax Pharmaceuticals Sees 2026 Total R&D Plus SG&A Expenses Approximately $400 M>SNDX - Moomoo
Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan
Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp - Stock Titan
Syndax Pharmaceuticals | 8-K: Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Syndax (NASDAQ: SNDX) posts 224% Q1 revenue surge and lower loss - Stock Titan
Vanguard Capital Management holds 4.46M shares in Syndax (SNDX) - Stock Titan
Syndax Pharmaceuticals earnings face test as competition heats up By Investing.com - Investing.com India
Syndax Pharmaceuticals earnings face test as competition heats up - Investing.com UK
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):